The first adjuvant chemotherapy cycle after glioblastoma treatment is behind you. Now comes the harder question: is it working? Getting a clear answer is hard. MRI scans can mislead at this stage, blood counts show only part of what's happening, and your team uses criteria most patients haven't heard of to define progression. This article explains what real response evaluation looks like after cycle one, what warning signs suggest you need outside input, and how to access a second opinion without losing time.
What the First Chemotherapy Cycle Means in GBM Treatment
Most glioblastoma patients follow the Stupp protocol: six weeks of concurrent radiation plus daily low-dose temozolomide (a chemotherapy taken as a pill), followed by six to twelve monthly adjuvant cycles of higher-dose temozolomide taken for five days each month. The first adjuvant cycle starts a few weeks after radiation ends.
This timing makes reading the results harder. Right after chemoradiation ends is one of the most difficult times for reading MRI scans - for biological reasons explained below. Understanding this helps you interpret what your team tells you and identify which questions are worth asking.
What Should an MRI Show After the First Glioblastoma Chemo Cycle?
Most oncologists schedule the first response MRI after two or three adjuvant cycles - not after just the first. The scan looks for stable or reduced contrast-enhancing tumor using the RANO scoring framework. If an MRI in the first 12 weeks shows worsening, your team will order a second scan to confirm before declaring true progression.
Oncologists assess response using a formal framework called the Response Assessment in Neuro-Oncology criteria - RANO for short. A 2023 update called RANO 2.0 revised several key rules and is now used at most major cancer centers. The core categories are:
- Complete response: No visible enhancing tumor on MRI, patient is off steroids, and neurologically stable.
- Partial response: At least a 50 percent reduction in the enhancing tumor area.
- Stable disease: Changes too small to meet the threshold for either response or progression.
- Progressive disease: At least a 25 percent increase in the enhancing tumor, a new lesion, or clear neurological decline.
An important RANO 2.0 change: for newly diagnosed patients, the MRI taken after completing radiotherapy - not the post-surgery scan - is now used as the baseline for measuring changes. Post-surgical scans often show enhancement caused by the operation itself, which can make the tumor appear larger before adjuvant treatment even begins.
The Pseudoprogression Problem: When the Scan Misleads
Here is the biggest challenge in early evaluation. After completing chemoradiation, about 30 to 40 percent of GBM patients - according to research - will have an MRI that looks like tumor growth when the real cause is treatment-related swelling and immune activity. Doctors call this pseudoprogression, which means false progression.
On the scan, pseudoprogression looks like worsening enhancement - the bright area appears larger. But the change comes from swelling of brain tissue and immune activity triggered by radiation and temozolomide, not from more tumor cells. Without follow-up imaging, this can look like real progression. Then doctors might stop a treatment that's actually working.
RANO 2.0 addresses this directly. In the first 12 weeks after completing chemoradiation, one scan showing worsening enhancement is not enough to prove true progression. Your team will order a repeat MRI, and sometimes other imaging like perfusion scans. If it's still unclear, a biopsy might be needed before changing your treatment. After 12 weeks, your team usually won't order a second scan unless the picture is unclear.
Patients with MGMT-methylated tumors appear to have higher rates of pseudoprogression. MGMT-methylated means your tumor has a chemical change that makes temozolomide more effective. If you're unsure whether MGMT testing was done or what your result means, this is something to clarify before your team draws conclusions from a single scan. Our article on pseudoprogression in glioblastoma covers the imaging patterns and clinical decision process in more detail.
What Blood Tests Tell You After Cycle One
MRI gets most of the attention, but blood work is also important. Temozolomide weakens bone marrow - the tissue that makes blood cells. Two values matter most:
- Lymphocytes: A type of white blood cell that fights infection. A significant drop - called lymphopenia - is common with temozolomide and affects when the next cycle can safely start.
- Platelets: Cells that support blood clotting. Low platelets - called thrombocytopenia - are a standard reason to delay or reduce the next temozolomide dose.
Your care team will check your blood count before each cycle and sometimes in the middle of a cycle. If your counts are low, your oncologist may delay cycle two or lower the dose. This is a standard safety step, not a sign that treatment has failed.
Feeling tired during this time is common. It comes from low blood counts, the effects of radiation, and often from taking dexamethasone (a steroid to reduce brain swelling). Some patients look for ways to support their health during this period. Ayurvedic products are available, but talk to your care team before adding anything new to your treatment.
For a fuller guide to what to expect from temozolomide and how to manage the most common side effects during the adjuvant phase, see our article on managing temozolomide side effects during GBM treatment.
Signs That Your Treatment Plan May Need Outside Review
Most patients complete the first cycle with manageable side effects and a stable scan. Some situations, however, warrant more than routine follow-up.
Consider seeking outside review if:
- Your MRI within the first 12 weeks shows new or worsening enhancement and your team has not mentioned pseudoprogression as a possible cause.
- Your tumor has not been fully tested for MGMT methylation and IDH mutation status, and no one has explained how these results affect your treatment plan.
- Side effects from cycle one were severe enough that you're not sure you can complete the full adjuvant course.
- You're not sure if your center regularly treats GBM, or if a full team (neurosurgeon, radiation oncologist, medical oncologist, and neuropathologist) reviewed your case before starting treatment.
- Your team has not raised the question of clinical trial eligibility.
None of these gaps necessarily means your current team is wrong. They do mean you should get more information.
When to Seek a Second Opinion After Chemotherapy Has Started
Getting a second opinion after your first chemotherapy cycle is not disloyal. It is standard practice at any major cancer center. The National Brain Tumor Society recommends that brain tumor patients always seek a second opinion when possible - and this matters especially at decision points like the first response assessment, when the team is deciding whether the current plan should continue.
A second opinion at this stage typically covers:
- An independent review of the original pathology slides and molecular profiling results.
- Assessment of the post-radiotherapy MRI compared with any subsequent scan, with a focus on distinguishing pseudoprogression from true progression.
- A check on whether the current treatment plan aligns with current RANO-based and guideline-driven standards.
- A review of whether any clinical trial or off-label option is relevant to your tumor's specific molecular profile.
You do not need to travel to access this. Your pathology slides and MRI files can be sent electronically, and most major neuro-oncology centers offer video consultations. If you are managing this on behalf of a family member and want clarity before the next cycle starts, a remote review is often the quickest way to get another doctor's opinion. You can arrange a remote second opinion, often before your next cycle, using your existing scans and reports.
For a step-by-step guide to gathering the materials a second opinion team will need, see our article on preparing your records for a remote glioblastoma second opinion.
Six Questions to Ask Your Oncologist After Cycle One
- What did my blood counts from cycle one show, and are we starting cycle two on schedule?
- When will you order the first response MRI, and what specifically will you be looking for?
- If the scan shows changes, how will you distinguish pseudoprogression from true progression?
- Do you have my complete molecular profile, including MGMT methylation and IDH mutation status?
- Is there a clinical trial I should be assessed for, given my tumor biology and where I am in treatment?
- What specific findings would prompt a change in the treatment plan at this point?
Recording the appointment with your oncologist's permission - or bringing a family member who can take notes - helps retain the answers accurately for later review.
A Note on the 12-Week Window
Most oncologists will not change a treatment plan based on a single scan showing mild changes, particularly within the first 12 weeks of completing chemoradiation. If your team pushes for a quick treatment change without a confirmation scan or second opinion, ask them to explain the RANO criteria and what findings would justify that change.
The National Brain Tumor Society notes that patients benefit from having their case reviewed at a center with specific expertise in brain tumors - particularly at complex decision points. If you are organizing records and want a consolidated review before your team meets to assess your response, you can upload your scans and reports through the Glioblastoma Center patient journey form to request a structured remote review.
When to Talk to Your Doctor
Contact your oncology team promptly - or go to an emergency department - if you develop new or worsening headaches, seizures, speech difficulties, vision changes, or limb weakness at any point between chemotherapy cycles. These symptoms can signal increased brain swelling or other changes that need prompt assessment and should not be watched at home.
Also contact your care team if:
- Blood counts from cycle one were significantly suppressed and you have not had a follow-up check.
- You have not received a clear explanation of what your most recent MRI showed, or what the plan is if the next scan looks worse.
- You want to discuss clinical trial eligibility before cycle two begins.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.